Resistance to BRAF inhibition in melanomas

N Engl J Med. 2011 Feb 24;364(8):772-4. doi: 10.1056/NEJMcibr1013704.
No abstract available

MeSH terms

  • Drug Resistance, Neoplasm
  • Enzyme Activation / drug effects*
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Indoles / pharmacology
  • Indoles / therapeutic use*
  • MAP Kinase Signaling System / drug effects
  • Melanoma / drug therapy*
  • Melanoma / enzymology
  • Melanoma / genetics
  • Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors
  • Mutation
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Proto-Oncogene Proteins B-raf / genetics
  • Sulfonamides / pharmacology
  • Sulfonamides / therapeutic use*
  • Vemurafenib

Substances

  • Indoles
  • Sulfonamides
  • Vemurafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Mitogen-Activated Protein Kinase Kinases